

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Hematology</b>				
Polycythemia	Endothelial PAS domain protein 1 (EPAS1; HIF2A)	A study in mice suggests that reducing HIF2A levels could help treat Chuvash polycythemia, a condition partly characterized by pulmonary hypertension and increased respiratory rate. In a mouse model of Chuvash polycythemia, <i>Hif2a</i> heterozygotes showed milder polycythemia and pulmonary symptoms than animals with two functional copies of <i>Hif2a</i> . Next steps include evaluating the use of HIF inhibitors in the mouse model of Chuvash polycythemia.	Work unpatented; unavailable for licensing	Hickey, M.M. <i>et al. J. Clin. Invest.</i> ; published online Feb. 8, 2010; doi:10.1172/JCI36362 <b>Contact:</b> M. Celeste Simon, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: <a href="mailto:celeste2@mail.med.upenn.edu">celeste2@mail.med.upenn.edu</a>
<b>SciBX 3(9); doi:10.1038/scibx.2010.279</b> Published online March 4, 2010				